Loading clinical trials...
Loading clinical trials...
Efficacy of Chimeric Monoclonal Anti-CD20 Antibodies (Rituximab Biosimilar) Associated With Monoclonal Anti-CD38 (Daratumumab) in the Treatment of Childhood Multidrug Dependent and Resistant (MDNS, MRNS) Nephrotic Syndrome
Conditions
Interventions
Rituximab Biosimilar ABP 798
Daratumumab
Locations
1
Italy
IRCCS G. Gaslini
Genova, Italy
Start Date
March 1, 2023
Primary Completion Date
March 1, 2024
Completion Date
March 1, 2025
Last Updated
October 31, 2023
NCT00001979
NCT00977977
NCT07305116
NCT05505500
NCT06607991
NCT06635720
Lead Sponsor
Istituto Giannina Gaslini
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions